Faculty

AGNELLI LUCA Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

PÉREZ-LOPEZ RAQUEL Vhio Radiomics Group, Barcelona

Tumori. Politecnico di Milano

Nazionale dei Tumori. Milano

dei Tumori, Milano IT

Tumori, Milano

PRELAJ ARSELA Fondazione IRCCS Istituto Nazionale dei

PROTO CLAUDIA Fondazione IRCCS Istituto Nazionale dei

PROVENZANO LEONARDO Fondazione IRCCS Istituto

SANCHEZ VEGA FRANCISCO Memorial Sloan Kettering New York

SPAGNOLETTI ANDREA Fondazione IRCCS Istituto Nazionale

TRUHN DANIEL RWTH Aachen University, Aachen Germany

VISCARDI GIUSEPPE Azienda Ospedaliera Monaldi Cotugno

Cto, Università degli Studi della Campania Luigi Vanvitelli, Napoli

RESTELLI MARCELLO Politecnico di Milano. DEIB

SANTORO EUGENIO Istituto Mario Negri Milano

SIGNORELLI DIEGO Niguarda Cancer Center,

Grande Ospedale Metropolitano Niguarda, Milano

TROVÒ FRANCESCO Politecnico di Milano, DEIB

VERLINGUE LOÏC Centre Leon Berard Lyon

VIBERT JULIEN Gustave Roussy, Villejuif France

SHAH SOHRAB Memorial Sloan Kettering New York

AMBROSINI EMILIA Politecnico di Milano, DEIB

BORACCHI GIACOMO Politecnico di Milano, DEIB

CICCHETTI ALESSANDRO Fondazione IRCCS Istituto
Nazionale dei Tumori, Milano

CRISPIN ORTUZAR MIREIA University of Cambridge

DE BRAUD FILIPPO Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

DE TOMA ALESSANDRO ASST Santi Paolo e Carlo, Ospedale San Paolo. Milano

DI MAIO MASSIMO President-elect of AIOM University of Turin, AOU Città della Salute e della Scienza di Torino, Ospedale Molinette

FERRARA ROBERTO IRCCS Ospedale San Raffaele, Milano

GANZINELLI MONICA Fondazione IRCCS Istituto Nazionale dei Tumori. Milano

GARASSINO MARINA CHIARA University of Chicago

GENNARI FRANCESCA Scuola Superiore Sant'Anna, Pisa

HO DEAN University of Singapore

KATHER JAKOB NIKOLAS Technical University Dresden

KOSTA SOKOL Aalborg University, Denmark

LO RUSSO GIUSEPPE Fondazione IRCCS Istituto Nazionale dei Tumori. Milano

MAZZEO LAURA Fondazione IRCCS Istituto Nazionale dei Tumori. Milano

MISKOVIC VANJA Politecnico di Milano, DEIB

MONZANI DARIO University of Palermo, IEO Milano

PEARSON ALEXANDER T. University of Chicago

PEDROCCHI ALESSANDRA Politecnico di Milano. DEIB

UNDER THE AUSPICES OF



ASCO® is a registered trademark of the American Society of Clinical Oncology®.

Used with permission. This is not an ASCO sponsored event."









WITH THE UNCONDITIONAL SPONSORSHIP OF

PLATINUM SPONSOF



GOLD SPONSOR



SILVER SPONSOR









Johnson&Johnson






SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER



Events srl

Via Lorenzo Lotto 9, 60019 Senigallia (AN) www.events-communication.com segreteria@events-communication.com Ph. +39 071 7930220 Fax. +39 071 9252094











PRESIDENT OF THE CONFERENCE

Arsela Prelaj, MD, PhD Candidate

Medical Oncologist and PhD student in Bioengineering and Artificial Intelligence

Politecnico di Milano

Thoracic Oncology Unit, Medical Oncology Department 1 Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy) Member of the ESMO Working Group on Real World Data and Digital Health

SCIENTIFIC COMMITTEE

Filippo de Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)

Alessandra Pedrocchi, Francesco Trovò, Vanja Miskovic Politecnico di Milano, DEIB

SCIENTIFIC SECRETARIAT

Giovanni Scoazec, Leonardo Provenzano Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)

General Information

CONGRESS VENUE

Aula Magna, Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, 1 20133 Milan (Italy)

VIRTUAL CONFERENCE

https://www.events-fad.com/

REGISTRATION

Registration is free of charge.
You may register for IN-PERSON OR ONLINE-ONLY ACCESS www.events-communication.com/event/ai2024

OFFICIAL LANGUAGE AND TIME

The official language is English
The official Time is Central European Summer Time (CEST), UTC +2

CME CREDITS

CME accreditation (valid for Italian participants only) for: Medical Doctor, Chemist, Pharmacist, Biologist, Physician,

CME credits RES: 4,9 - CME credits FAD: 10,5

talian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the question-naire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

Overview

Al methodologies have been applied to medical research for years, and have recently made an impactful entrance in oncology more specifically. Al broadly speaking consists in a set of techniques allowing computers to emulate human intelligence, employing algorithms created for the analyses and the design of either predictions or conclusions based on the analysis of big datasets.

The latter is especially important for cancer research considering the critical mass of data available for analysis and that standard analysis methods fail to exploit to its fullest potential. This is particularly the case for multiomics data, with their high variation in nature, format or storage. The proper and effective and integration of these novel methodologies into the standards of clinical – but also basic and translational – research could prove to be an important leap forward for oncology research. Hence, this event will

have two core training objectives.

The first will be to ease the clinical and research community into the field of AI methodologies themselves, still misunderstood or not known to its full potential – from a general overview of the most frequently used ML/DL methods and Explainable AI to a deep dive in novel data platforms and repository structures integrating these approaches in their design. This will allow clinicians to identify the value of AI models for their trials and studies, making the volume of patient – and tumor-related data valuable and more fully exploitable; as well as biologists to assess its potential in tumor biology to discover new biomarkers and mechanisms.

The second main endpoint will be to demonstrate not only the possibilities offered by the inclusion of Al models in standard practice, but really to present some concrete and innovative activities where they are already being successfully implemented. The focus is to demonstrate in particular the value of Al for both its predictive power and for the possibilities it opens up for the discovery of both new biomarkers and of new molecules targeting specific tumors. In particular, one section will be focused on the translational field and the synergy between Al-powered multiomic data analysis and clinical research, with regards to cancer

immunotherapy, for example metastatic lung cancer.

In this context, we will showcase and discuss ongoing projects, including I3LUNG, along with other initiatives focused on the diagnostic and treatment pathways optimization for lung cancer patients. These projects involve collaboration among research institutes, academia, and private companies. As the AI research field is evolving at a rapid pace, the event will be topped off by a session offering perspectives already going beyond the current state of the art and providing insights into the Artificial Intelligence of tomorrow – how it could be involved as full-fledged actor in clinical decision-making.

FORMAT

The event is set to be a full-day program. The speakers will have a diverse background to reflect the spectrum of Artificial Intelligence research (and beyond), from Artificial Intelligence engineering experts, to clinicians and translational researchers, and hybrid figures such as clinical Artificial Intelligence specialists. The attendance is expected to mirror this variety, along with participants with a more specific background in imaging and pathology.

ABSTRACT SUBMISSION CLOSED

Abstract submission is now closed.

The results of the abstract submission will be available on 04th March. Check your emails!

TOPIC AREAS:

- 1.Cancer screening with Al
- 2. Image diagnosis (radiomics and/or digital pathology)
- 3. Multiomics and/or Multimodal Integration with Al
- 4. Treatment prediction and Selection with AI and explainability
- 5. Special Section (Al legal-ethical frameworks, Innovative platforms and Cognitive sensing and wearable devices)

SUBMISSION DEADLINES:

31th January 2024 submission deadline 04th March 2024 outcome notifications

Scientific Program

08:30 POSTER SESSION

09:30 Welcome
Arsela Prela

Gustavo Galmozzi President Fondazione IRCCS
Istituto Nazionale dei Tumori

Carlo Nicora General Director Fondazione IRCCS Istituto Nazionale dei Tumori

Giovanni Apolone Scientific Director Fondazione IRCCS

Istituto Nazionale dei Tumori

Filippo de Braud Director Dpt. of Oncology and
Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori

Bruno Aratri President IPOP Onlus

Introduction

Introduction
 Massimo Di Majo President-elect of AIOM

session 1

BACKGROUND ON AI METHODOLOGIES AND THEIR USE IN THE CLINICAL PRACTICE

Chairs: Francisco Sanchez Vega, Monica Ganzinelli, Francesco Trovò

10:00 Machine, Deep Learning and Reinforcement Learning in medicine

Marcello Restelli

10:20 Explanable AI for RWD, genomics and gaps in images Vania Miskovic

10:40 Deep Learning applied to Genomics and Transcriptomics

Julien Vibert

11:00 Discussion

session 2

AI AND IMAGING: CLINICAL PRACTICE APPLICATION AND FUTURE DIRECTIONS

Chairs: Andrea Spagnoletti, Alessandro Cicchetti, Giacomo Boracchi

11:20 Integration of radiomics in clinical practice for screening and diagnosis

Mireia Crispin Ortuzar

11:40	The use of radiomics in prediction: treatment outcomes and toxicity Raquel Pérez-Lopez
12:00	Integration of digital pathology in clinical practice for screening and diagnosis Jakob Nikolas Kather
12:20	The use of digital pathology in prediction: treatment outcomes and toxicity Alexander T. Pearson
12:40	Discussion
13:00	Lunch Break POSTER SESSION
session 3	

Session 3 ALFOR OMICS AND MULTIMODAL DATA ANALYSIS

Chairs: Alessandra Pedrocchi, Arsela Prelaj, Luca Agnelli

14:00 Multimodal integration: from methodology to its successful application

Sohrab Shah

14:20 Shared talk: Molecular Tumor Board and the role of Al: the oncologist and Al-expert point of view

Filippo de Braud, Loic Verlingue

14:45 Drug discovery using virtual Al lab - Special lecture

Marina Chiara Garassino

15:05 Discussion

session 4

DATA STORAGE AND ITS REGULATORY FRAMEWORK

Chairs: Sokol Kosta, Emilia Ambrosini, Laura Mazzeo

15:25 Bridging the Gap: Federated Learning as a Catalyst for Collaborative Development of Al Models
 Daniel Truhn

 15:45 Digital therapeutics: clinical applications in oncology

16:05 Al and the MDR: between compliance and liability

16:25 Discussion

Eugenio Santoro

16:40 Coffee Break **POSTER SECTION**

session 5

SPECIAL SECTION AND PROJECTS

Chairs: Giuseppe Lo Russo, Claudia Proto, Diego Signorelli

17:20 Accelerating Clinical Trials with Al-powered medical platforms for personalized dosing and Digital Twins

Dean Ho

17:40 Updates on the I3LUNG Horizon Europe Project Leonardo Provenzano

17:50 Patients Decision Aid using Al tools Dario Monzani

18:00 Discussion

session 6

AWARDS (NO CME SESSION)

Chairs: Giuseppe Viscardi, Alessandro De Toma, Roberto Ferrara

18.10 Introduction

18:15 Deep Learning-Based Tool for Detection and Discrimination of Breast Microcalcification on Mammography
Filippo Pesapane

18:20 Modelling toxicity after prostate cancer radiotherapy using genetically guided Voxel-Based Analysis
Nicola Rares Franco

18:25 Best poster award
The winner

18:30 Farewell and take-home messages
Arsela Prelaj